#SARS-CoV-2

Previous studies of the association between tenofovir and the coronavirus have yielded mixed results.

A study from the Leukemia & Lymphoma Society finds that antibody production varies widely across blood cancer types.

Two new studies come to different conclusions about the risk for severe illness and death.

The results point the way toward a universal coronavirus vaccine that could prevent future pandemics.

Rapid test results are needed to interrupt the chain of coronavirus transmission.

The immune response to the single-shot Johnson & Johnson vaccine remained robust against variants of SARS-CoV-2.

Some people with blood cancers, however, may not be as well protected.

MOMI-VAX researchers will evaluate antibody responses in vaccinated participants and their infants.

An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.

Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.

The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats

Researchers found antibodies against the virus that causes COVID-19 in blood samples collected as early as January 2020.

The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.

The trial will inform public health policy on the potential use of mixed vaccine schedules if booster doses are needed.

Research suggests how to develop more broadly effective therapies and vaccines.

After reviewing thousands of blood donations, researchers found no reason to alter current screening practices.